Open an account

Jazz Pharmaceuticals

JAZZ · NASDAQ

$213.76+$5.33 (+2.56%)TodayMarket closed ·
Prev close $208.43

About JAZZ

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. The company is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. The company has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.

Employees
2,890
Headquarters
DUBLIN, Dublin
Listed
Jan 18, 2012
Sector
Health Care
Industry
Pharmaceuticals
Website
jazzpharma.com

JAZZ key statistics

Market cap
13.53B
Price-earnings ratio
14.25
Dividend yield
—
Average volume
806.84K
Volume
662.95K
Open price
$209.89
High today
$215.55
Low today
$208.98
52 Week high
$266.38
52 Week low
$128.80

Jazz Pharmaceuticals (JAZZ) at a glance

Jazz Pharmaceuticals (JAZZ) last traded at $213.76, with a market cap of 13.53B and a price-to-earnings ratio of 14.25.

Today the stock has traded between $208.98 and $215.55. The current price is 2.3% above the day's low and 0.8% below its high.

Volume so far is 662.95K shares, in line with the average of 806.84K shares a day.

Over the past year Jazz Pharmaceuticals has ranged from $128.80 to $266.38, and now sits 62% of the way up that range.

Jazz Pharmaceuticals met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported $5.71 per share against an estimate of $6.30.

The average analyst price target is $299.83, 40.3% above the current price, from 20 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

95%of 20 analyst ratings say Buy
  • Buy95.0%
  • Hold5.0%
  • Sell0.0%
Price target · 24 analystsAvg $299.83
Low
$201.92
Now
$213.76
High
$353.85

JAZZ earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 25.0% on average.

  1. Q3 FY24: reported $6.61 per share against an estimate of $5.61
  2. Q4 FY24: reported $6.60 per share against an estimate of $5.93
  3. Q1 FY25: reported $1.68 per share against an estimate of $4.75
  4. Q2 FY25: reported -$8.25 per share against an estimate of -$7.76
  5. Q3 FY25: reported $8.13 per share against an estimate of $6.04
  6. Q4 FY25: reported $6.64 per share against an estimate of $6.65
  7. Q1 FY26: reported $6.34 per share against an estimate of $4.66
  8. Q2 FY26: reported $5.71 per share against an estimate of $6.30

JAZZ news

  • Press releasePRNewswire

    Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026

  • Radhika Anilkumar Nadig

    Nvidia-Backed AI Drug Discovery Company Iambic Therapeutics Files for Nasdaq IPO, to Use Proceeds for Cancer Drug Development

  • Press releasePRNewswire

    Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

  • Press releasePRNewswire

    Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

  • Press releasePRNewswire

    Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA

  • Press releasePRNewswire

    Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases

  • Press releasePRNewswire

    Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases

  • Vandana Singh

    What'sGoing On With AbCellera Biologics Stock On Tuesday?

Similar companies

Companies in the same industry as Jazz Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.